Global Healthcare Study on Hidradenitis Suppurativa
GHSHS
1 other identifier
observational
9,600
1 country
1
Brief Summary
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2025
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
June 15, 2026
CompletedFirst Posted
Study publicly available on registry
June 22, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2029
June 22, 2026
June 1, 2026
5 years
June 15, 2026
June 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
International Hidradenitis Suppurativa Severity Score System (IHS4)
Clinician-assessed measure of hidradenitis suppurativa severity based on the number of inflammatory nodules, abscesses, and draining tunnels; higher scores indicate more severe disease.
Baseline and follow-up visits every 6-12 months for up to 5 years.
Secondary Outcomes (6)
Hurley Staging System
Baseline and follow-up visits every 6-12 months for up to 5 years.
Sartorius Hidradenitis Suppurativa Severity Score (HSS)
Baseline and follow-up visits every 6-12 months for up to 5 years.
Physician Global Assessment (PGA)
Baseline and follow-up visits every 6-12 months for up to 5 years.
Dermatology Life Quality Index (DLQI)
Baseline and follow-up visits every 6-12 months for up to 5 years.
Patient-reported Numerical Rating Scale (NRS) for severity of hidradenitis suppurativa
Baseline and follow-up visits every 6-12 months for up to 5 years.
- +1 more secondary outcomes
Eligibility Criteria
Patient populations across world regions seen for hidradenitis suppurativa.
You may qualify if:
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Hidradenitis Suppurativa
You may not qualify if:
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Julia Tatjana Maullead
- University of Zurichcollaborator
- University Hospital, Zürichcollaborator
Study Sites (1)
University of Zurich
Zurich, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Julia-Tatjana Maul, Prof. Dr. med.
University of Zurich
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. med.
Study Record Dates
First Submitted
June 15, 2026
First Posted
June 22, 2026
Study Start
January 1, 2025
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2029
Last Updated
June 22, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share